RT Journal Article
SR Electronic
T1 A comparison of Remdesivir versus Au<sub>22</sub>Glutathione<sub>18</sub> in COVID-19 golden hamsters: a better therapeutic outcome of gold compound
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.10.16.342097
DO 10.1101/2020.10.16.342097
A1 Zhesheng He
A1 Fei Ye
A1 Chunyu Zhang
A1 Jiadong Fan
A1 Zhongying Du
A1 Wencong Zhao
A1 Qing Yuan
A1 Wenchao Niu
A1 Fuping Gao
A1 Bo He
A1 Peng Cao
A1 Lina Zhao
A1 Xuejiao Gao
A1 Xingfa Gao
A1 Bo Sun
A1 Yuhui Dong
A1 Jincun Zhao
A1 Jianxun Qi
A1 Huaidong Jiang
A1 Yong Gong
A1 Wenjie Tan
A1 Xueyun Gao
YR 2021
UL http://biorxiv.org/content/early/2021/09/03/2020.10.16.342097.abstract
AB We firstly disclose single compound yields better therapeutic outcome than Remdesivir in COVID-19 hamster treatments as it is armed with direct inhibition viral replication and intrinsic suppression inflammatory cytokines expression. Crystal data reveals that Au (I), released from Au22Glutathione18 (GA), covalently binds thiolate of Cys145 of SARS-CoV-2 Mpro. GA directly decreases SARS-CoV-2 viral replication (EC50: ~0.24 μM) and intrinsically down-regulates NFκB pathway therefore significantly inhibiting expression of inflammatory cytokines in cells. The lung viral load and inflammatory cytokines in GA-treated COVID-19 transgenic mice are found to be significantly lower than that of control mice. When COVID-19 golden hamsters are treated by GA, the lung inflammatory cytokines levels are significantly lower than that of Remdesivir while their lung viral load are decreased to same level. The pathological results show that GA treatment significantly reduce lung inflammatory injuries when compared to that of Remdesivir-treated COVID-19 golden hamsters.One Sentence Summary We found that gold cluster molecule directly inhibits SARS-CoV-2 replication and intrinsically suppresses inflammatory cytokines expression in COVID-19 transgenic mouse and golden hamster model, gold cluster providing a better lung injury protection than Remdesivir in COVID-19 golden hamsters via intranasally dropping administration.Competing Interest StatementThe authors have declared no competing interest.